The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage Information for Adult Hodgkin Lymphoma

Added Dann et al. as reference 7, Gallamini et al. as reference 8, and Advani et al. as reference 9 .

Added text about a prospective multinational study of 260 newly diagnosed patients with HL, with baseline PET scans, who were treated with two cycles of ABVD and the 2-year progression-free survival was 12.8% with a positive PET scan and 95% with a negative PET scan.

Treatment Option Overview

Added text about an observed increase in second solid tumors, especially cancers of the colon and rectum and mesothelioma (cited Hodgson et al. as reference 15).

Added text about a cohort of 5-year survivors from 13 population-based registries in which the younger patients had elevated risks for breast and colorectal cancer 10 to 25 years before the age when routine screening would be recommended in the general population.

Added van der Kaaij et al. as reference 34.

Added text about late complications primarily related to radiation therapy that may persist through to 25 years after first treatment (cited Swerdlow et al. as reference 41).

Added text about a cohort of HL patients in which the myocardial infarction mortality risk persisted through to 25 years after first treatment with supradiaphragmatic radiation therapy, doxorubicin, or vincristine.

Early Favorable Hodgkin Lymphoma

Added bullet to drug combinations list: MOPP-ABV: mechlorethamine plus vincristine plus procarbazine plus prednisone plus doxorubicin plus bleomycin plus vincristine.

Added text about a randomized prospective trial involving 542 patients with early favorable HL that compared MOPP-ABV plus IF-XRT with subtotal nodal radiation; with a median follow-up of 7.7 years, combined modality was favored in terms of 5-year event-free survival and 10-year overall survival (cited Fermé et al. as reference 1 and level of evidence: 1iiA).

Added Swerdlow et al. as reference 5 and Engert et al. as reference 6.

Early Unfavorable Hodgkin Lymphoma

Added bullet to drug combinations list: MOPP-ABV: mechlorethamine plus vincristine plus procarbazine plus prednisone plus doxorubicin plus bleomycin plus vincristine.

Added Swerdlow et al. as reference 5 and Engert et al. as reference 6.

Added text about a randomized study of 996 patients with early unfavorable HL that showed no difference in overall survival and event-free survival at 10 years comparing four to six cycles of MOPP-ABV plus IF-XRT versus the same chemotherapy plus subtotal nodal radiation therapy (cited Fermé et al. as reference 11 and level of evidence: 1iiA).

Back to Top

< Previous Section  |  Next Section >